Akihiro Seki

1.8k total citations
41 papers, 801 citations indexed

About

Akihiro Seki is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Akihiro Seki has authored 41 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Hepatology and 12 papers in Epidemiology. Recurrent topics in Akihiro Seki's work include Lung Cancer Treatments and Mutations (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver physiology and pathology (7 papers). Akihiro Seki is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Liver physiology and pathology (7 papers). Akihiro Seki collaborates with scholars based in Japan, United States and Belgium. Akihiro Seki's co-authors include Yoshio Sakai, Masao Honda, Takashi Wada, Shuichi Kaneko, Takuya Komura, Alessandro Nasti, Tatsuya Yamashita, Masayuki Takamura, Eishiro Mizukoshi and Taro Yamashita and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Scientific Reports.

In The Last Decade

Akihiro Seki

35 papers receiving 788 citations

Peers

Akihiro Seki
Tomohiro Kurokawa Japan
Mikio Kajihara Japan
Christoffer Soendergaard Denmark
J. Mann United Kingdom
Takahisa Kayahara Japan
I‐Wei Chang Taiwan
Jonathan M. Goodwin United States
Benyan Wu China
Takahiro Shimizu Japan
Yongqiang Li China
Tomohiro Kurokawa Japan
Akihiro Seki
Citations per year, relative to Akihiro Seki Akihiro Seki (= 1×) peers Tomohiro Kurokawa

Countries citing papers authored by Akihiro Seki

Since Specialization
Citations

This map shows the geographic impact of Akihiro Seki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Seki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Seki more than expected).

Fields of papers citing papers by Akihiro Seki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihiro Seki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Seki. The network helps show where Akihiro Seki may publish in the future.

Co-authorship network of co-authors of Akihiro Seki

This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Seki. A scholar is included among the top collaborators of Akihiro Seki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Seki. Akihiro Seki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terashima, Takeshi, Kouki Nio, Naohiko Koshikawa, et al.. (2025). Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. PubMed. 3(1). 2–2. 1 indexed citations
2.
Terashima, Takeshi, Makoto Yamamoto, Tadashi Toyama, et al.. (2025). The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma. Hepatology Research. 55(7). 1026–1037.
3.
Nasti, Alessandro, Akihiro Seki, Keiko Yoshida, et al.. (2025). Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer. Molecular Oncology. 19(5). 1452–1470. 1 indexed citations
4.
5.
Terashima, Takeshi, Tatsuya Yamashita, Kuniaki Arai, et al.. (2024). Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice. Hepatology International. 19(1). 212–221. 3 indexed citations
6.
Yamamoto, Makoto, Takeshi Terashima, Tatsuya Yamashita, et al.. (2024). Lenvatinib plus hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 42(3_suppl). 496–496.
7.
Canales-Herrerías, Pablo, Mathieu Uzzan, Akihiro Seki, et al.. (2024). OP39 Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signaling. Journal of Crohn s and Colitis. 18(Supplement_1). i69–i70.
8.
Nakanuma, Shinichi, Mitsuyoshi Okazaki, Akihiro Seki, et al.. (2023). Hemophagocytic Lymphohistiocytosis With Elevated Cytokines Related to Macrophage Activation After Liver Transplantation for Autoimmune Hepatitis: A Case Report. Transplantation Proceedings. 55(8). 1946–1950. 1 indexed citations
9.
Seki, Akihiro, Kazunori Kawaguchi, Alessandro Nasti, et al.. (2021). Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. Stem Cell Research. 54. 102425–102425. 11 indexed citations
10.
Takata, Noboru, Kiyo‐aki Ishii, Hiroaki Takayama, et al.. (2021). LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Scientific Reports. 11(1). 555–555. 41 indexed citations
11.
Nasti, Alessandro, Akihiro Seki, Takuya Komura, et al.. (2020). Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. Journal for ImmunoTherapy of Cancer. 8(2). e001367–e001367. 86 indexed citations
12.
Seishima, Jun, Noriho Iida, Kazuya Kitamura, et al.. (2019). Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome biology. 20(1). 252–252. 106 indexed citations
13.
Torres, Joana, Akihiro Seki, Leonid Tarassishin, et al.. (2018). DOP087 The gut microbiota of pregnant women with Crohn’s disease and their babies is associated with abnormalities in the adaptive immune system: results from the MECONIUM study. Journal of Crohn s and Colitis. 12(supplement_1). S087–S088. 1 indexed citations
14.
15.
Kato, Terufumi, Takashi Seto, Makoto Nishio, et al.. (2017). Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Safety. 41(2). 229–237. 44 indexed citations
16.
Yoshioka, Hiroshige, Kiyoshi Komuta, Fumio Imamura, et al.. (2014). Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. Lung Cancer. 86(2). 201–206. 29 indexed citations
17.
Furuse, Junji, Akihiko Gemma, Takashi Hatori, Takuji Okusaka, & Akihiro Seki. (2014). Final Safety Analysis of Erlotinib Plus Gemcitabine in a Post-Marketing Surveillance Study (Polaris) of >800 Japanese Pancreatic Cancer Patients. Annals of Oncology. 25. iv239–iv239. 1 indexed citations
18.
Seki, Akihiro, Yoshio Sakai, Takuya Komura, et al.. (2013). Adipose Tissue-Derived Stem Cells As A Regenerative Therapy for A Mouse Steatohepatitis-Induced Cirrhosis Model. Hepatology. 58(3). 1133–1142. 100 indexed citations
19.
Fukuoka, M., Satoshi Kudoh, Ken Nakagawa, et al.. (2011). Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients (Pts).. Journal of Clinical Oncology. 29(15_suppl). e18007–e18007. 1 indexed citations
20.
Nagahama, Masami, Akihiro Seki, Takashi Shinohara, et al.. (2004). NVL2 Is a Nucleolar AAA-ATPase that Interacts with Ribosomal Protein L5 through Its Nucleolar Localization Sequence. Molecular Biology of the Cell. 15(12). 5712–5723. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomohiro Kurokawa Breakdown of academic impact, for papers by Mikio Kajihara Breakdown of academic impact, for papers by Christoffer Soendergaard Breakdown of academic impact, for papers by J. Mann Breakdown of academic impact, for papers by Takahisa Kayahara Breakdown of academic impact, for papers by I‐Wei Chang Breakdown of academic impact, for papers by Jonathan M. Goodwin Breakdown of academic impact, for papers by Benyan Wu Breakdown of academic impact, for papers by Takahiro Shimizu Breakdown of academic impact, for papers by Yongqiang Li
Rankless by CCL
2026